Affinity Asset Advisors, LLC Annovis Bio, Inc. Transaction History
Affinity Asset Advisors, LLC
- $896 Million
- Q1 2025
A detailed history of Affinity Asset Advisors, LLC transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 72,900 shares of ANVS stock, worth $187,353. This represents 0.13% of its overall portfolio holdings.
Number of Shares
72,900Holding current value
$187,353% of portfolio
0.13%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding ANVS
# of Institutions
53Shares Held
2.08MCall Options Held
88.1KPut Options Held
188K-
Vanguard Group Inc Valley Forge, PA648KShares$1.67 Million0.0% of portfolio
-
Two Sigma Investments, LP New York, NY166KShares$427,1820.0% of portfolio
-
Ubs Group Ag161KShares$413,4510.0% of portfolio
-
Geode Capital Management, LLC Boston, MA153KShares$392,2150.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA128KShares$328,2010.0% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $21M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...